Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 45

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 45
---
litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure.

Our competitors, many of
which have made substantial investments in patent portfolios, trade secrets, trademarks and competing technologies, may have applied
for or obtained, or may in the future apply for or obtain, patents or trademarks that may prevent, limit or otherwise interfere with
our ability to make, use, sell and/or export our products or to use our technologies or product names. Moreover, individuals and groups
that are non-practicing entities, commonly referred to as “patent trolls,” purchase patents and other intellectual property
assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening
letters, notices or “invitations to license,” or may be the subject of claims that our products and business operations infringe
or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation,
divert management’s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make
substantial payments.

If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property or are unable to protect the confidentiality of our trade secrets, the value of our products and our business and competitive position could be harmed.

In addition to patent protection,
we also rely on protection of copyright, trade secrets, know-how and confidential and proprietary information. We generally enter into
confidentiality and invention assignment agreements with our employees, consultants and third parties upon their commencement of a relationship
with us. However, we may not enter into such agreements with all employees, consultants and third parties who have been involved in the
development of our intellectual property. In addition, these agreements may not provide meaningful protection against the unauthorized
use or disclosure of our trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or
disclosure were to occur. The exposure of our trade secrets and other proprietary information would impair our competitive advantages
and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to
protect our proprietary rights may allow competitors to copy our products and procedures, which could adversely affect our pricing and
market share. Further, other parties